Compare DexCom, Inc. (DXCM) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares MBS ETF — how do they compare? DexCom, Inc. trades at $77.98 (market cap $28.06B), while iShares MBS ETF trades at $93.83. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | MBB | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $96.91 |
52-Week Low | $54.84 | $92.62 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
MBB (iShares MBS ETF) trades at $93.77, up 0.1% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with key support/resistance clustered around $94. Recent institutional activity is mixed, with some firms increasing positions while others reduced holdings. The fund provides exposure to mortgage-backed securities and pays regular dividends, with recent distributions of $0.33-0.34 per share.
The ETF faces headwinds from interest rate sensitivity and housing market volatility, though its 4% yield provides income appeal. Technical weakness suggests near-term pressure, while institutional interest remains divided. Mortgage market stability and Fed policy will be key drivers for performance ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
